medigraphic.com

2009, Number 6

<< Back Next >>

Cir Cir 2009; 77 (6)

Factores de riesgo asociados a alteraciones histológicas del aparato genital en pacientes del primer nivel de atención

Hernández-Valencia M, Rodríguez-Lundes O, Landero-Montes ME, Pichardo-García R, Escamilla-Godínez G

Language: Spanish
References: 14
Page: 451-454
PDF size: 68.13 Kb.


ABSTRACT

Objective: We undertook this study to determine risk factors for histological alterations of the female genital tract in an open population that attends a first-level of care medical facility. Methods: We conducted a case/control cohort study that included patients from outpatient consultation who responded to a cervical cancer control and prevention program. We studied 1933 patients; 88 patients (cases) had cellular alterations and were matched with 88 patients without alterations (controls). Statistical analysis was carried out with one-way ANOVA for comparison between groups and association of variables with relative risk for 95% confidence interval; p ‹0.05. Results: Mean age of the case group was 36.1 ± 1.6 years and the control group had a mean age of 35.8 ± 2.1 years. Diagnoses obtained in the case group showed a greater frequency of ectropion, human papilloma virus infection and CIN 1. Risks factors analyzed in these patient showed statistical differences in number of gestation ›2 (RR = 2.33) and the early initiation of sexual activity ‹19 years (RR = 1.14) for experiencing histological problem of the female genital tract. Conclusions: Prevention of cervical cancer can be accomplished through timely and opportune detection in order to avoid the disease or to decrease risk factors by using condoms, delaying initiation of sexual activity and limiting the number of sexual partners. These are all strategies that the general population should be aware of.


REFERENCES

  1. Secretaría de Salud. Programa Nacional de prevención y control del cáncer cérvico uterino en México. México: Secretaría de Salud; 1997. pp. 1-13.

  2. Albert RH, Clark MM. Cancer screening in the older patients. Am Fam Physician 2008;78:1369-1374.

  3. Manci N, Marchetti C, Esposito F, Graziano M, Tomao F, Pastore M, et al. Late breast cancer recurrence to the uterine cervix with a review of the literature. Int J Gynecol Pathol 2008;27:113-117.

  4. Rodríguez A. Factores de riesgo del cáncer de cérvix en el municipio Cerro. Instituto Nacional de Higiene, Epidemiología y Microbiología. Cub Hig Epidemiol 1999;37:40-46.

  5. Rojas MR. Factores de riesgo reproductivo y cáncer cervicouterino en la ciudad de México. Salud Publica Mex 1993;35:78-82.

  6. Lazcano-Ponce E. Factores de riesgo reproductivo asociados a cáncer cervical en México. Rev Invest Clin 1995;47:377-385.

  7. Ojeda OJ, Muñoz MR, Pardo LM, Guevara CM, Hernández QT, Valencia EC, Hernández-Valencia M. Comparación de la toma de citología cervical con calidad satisfactoria con el método Cervex-brush o Cervex-mex. Ginecol Obstet Mex 2008;76:381-385.

  8. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States 2003-2005. Ann Intern Med 2008;148:I32-I36.

  9. Hans N, Cave AJ, Szafran O, Johnson G, Glass A, Spooner GR, et al. Papanicolaou smears: to swab or not to swab. Can Fam Physician 2007;53:1328-1329.

  10. Chute DJ, Covell J, Pambuccian SE, Stelow EB. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests. Diagn Cytopathol 2006;34:503-506.

  11. Hernández QT, Illanes AB, Salas LN, Alarcón RLC, Hernández-Valencia M. Evaluación del tratamiento con imiquimod en infección persistente por el virus del papiloma humano con el método de reacción en cadena de la polimerasa. Ginecol Obstet Mex 2006;74:317-326.

  12. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12:6167-6171.

  13. Secretaría de Salud. Norma oficial mexicana para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cervicouterino. NOM-014-SSA2-2007. Diario Oficial de la Federación, 15 de enero de 1995. pp. 1-20.

  14. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm 2007;4:8-10.




2020     |     www.medigraphic.com